Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Alzheimer's Disease
NCT07332260Phase 1Recruiting
- Sponsor
- University Hospital of North Norway
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in Alzheimer's disease (AD), sponsored by University Hospital of North Norway. Primary endpoints: Incidence of treatment-related adverse events and serious adverse events at 3 months, Rate of participant recruitment at 1 year and 5 more. Started May 2026; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07332260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332260.